10 Best All-Time Low Stocks To Buy Right Now

5. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Number of Hedge Fund Holders In Q3 2024: 30

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a Massachusetts-based pre-revenue stage biotechnology company. The firm focuses on developing treatments primarily used to treat cancer and tumors. Since Relay Therapeutics, Inc. (NASDAQ:RLAY) has yet to generate revenue, its hypothesis is dependent on its under-trial drugs. On this front, the firm’s leading drug candidate is its breast cancer drug called RLY-2608. Relay Therapeutics, Inc. (NASDAQ:RLAY) benefits from the fact that a treatment developed by Roche which uses a similar mechanism to RLY-2608 to treat cancer has procured FDA’s approval. While the approval increases competition for Relay Therapeutics, Inc. (NASDAQ:RLAY), it also increases the possibility of a successful product launch to help the firm generate revenue. Consequently, the stock’s performance depends on Relay Therapeutics, Inc. (NASDAQ:RLAY)’s ability to provide a superior alternative to Roche and AstraZeneca’s products on metrics such as tolerability.